Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
← catalyst calendarSponsored by DBV Technologies (industry) · DBV.PA — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
600estimated
Sites
87
Countries
Australia, Canada, France +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-02-21 | actual | When the study began enrolling |
| Primary completion | 2025-11-06 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Allergy, Peanut
Interventions
- Drug: DBV712 — also filed as ViaskinTM Peanut
- Other: Placebo
- Drug: DBV712 — also filed as ViaskinTM Peanut
Primary outcome
what the primary-completion date above is the date OFDBPC Treatment Period: Percentage of Treatment Responders in the DBV712 250 mcg Group Compared to Placebo Group
measured At Month 12
Permalink · DBV.PA's whole pipeline · Catalyst calendar · Every registered study · What changed